E!4408, COZY01, CombiGene AB
| Reference number | |
| Coordinator | CombiGene AB |
| Funding from Vinnova | SEK 1 274 599 |
| Project duration | February 2024 - September 2025 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
The project aimed to develop a new peptide treatment for chronic pain. The goal and expected results were not achieved because CombiGene AB had to end its participation in the project. The Board of CombiGene AB decided to stop all research activities and collaborations. As a result, CombiGene could not continue the Eurostars project and formally ended its participation in January 2025. This decision led to the termination of the entire project.
Expected long term effects
The early termination of CombiGene’s participation in the project led to the end of the project and stopped the delivery of expected results. As a result, no long-term effects are expected.
Approach and implementation
CombiGene was the lead partner in a consortium formed together with the Danish company Zyneyro. The project started as planned, despite some minor challenges and delays in the technical work, mainly related to studying COZY01 target engagement in human tissue. CombiGene and Zyneyro worked closely together to implement the project, and the collaboration worked well. However, CombiGene AB was forced to end its participation in the project, which led to the termination of the entire project.